• Mezzion Pharma agreed Nov. 4, 2026, to sell Australian udenafil patents to Hepaguard (International) for USD 4 million.
• The deal transfers full ownership of two patents covering udenafil treatments for Fontan patients and single-ventricle heart disease.
• Payments of USD 2 million each are due by Dec. 31, 2026, and Feb. 28, 2027.
• The transfer does not affect development or commercialization rights for udenafil, its lead pipeline drug.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mezzion Pharma Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261104900242), on November 04, 2026, and is solely responsible for the information contained therein.